ANA AMELIA FIALHO DE OLIVEIRA HOFF
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina - Médico
13 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 13
- Comparison of Pheochromocytoma-Specific Morbidity and Mortality Among Adults With Bilateral Pheochromocytomas Undergoing Total Adrenalectomy vs Cortical-Sparing Adrenalectomy(2019) NEUMANN, Hartmut P. H.; TSOY, Uliana; BANCOS, Irina; AMODRU, Vincent; WALZ, Martin K.; TIROSH, Amit; KAUR, Ravinder Jeet; MCKENZIE, Travis; QI, Xiaoping; BANDGAR, Tushar; PETROV, Roman; YUKINA, Marina Y.; ROSLYAKOVA, Anna; HORST-SCHRIVERS, Anouk N. A. van der; BERENDS, Annika M. A.; HOFF, Ana O.; CASTRONEVES, Luciana Audi; FERRARA, Alfonso Massimiliano; RIZZATI, Silvia; MIAN, Caterina; DVORAKOVA, Sarka; HASSE-LAZAR, Kornelia; KVACHENYUK, Andrey; PECZKOWSKA, Mariola; LOLI, Paola; ERENLER, Feyza; KRAUSS, Tobias; ALMEIDA, Madson Q.; LIU, Longfei; ZHU, Feizhou; RECASENS, Monica; WOHLLK, Nelson; CORSSMIT, Eleonora P. M.; SHAFIGULLINA, Zulfiya; CALISSENDORFF, Jan; GROZINSKY-GLASBERG, Simona; KUNAVISARUT, Tada; SCHALIN-JANTTI, Camilla; CASTINETTI, Frederic; VLCEK, Petr; BELTSEVICH, Dmitry; I, Viacheslav Egorov; SCHIAVI, Francesca; LINKS, Thera P.; LECHAN, Ronald M.; BAUSCH, Birke; YOUNG JR., William F.; ENG, Charis; JAISWAL, Sanjeet Kumar; ZSCHIEDRICH, Stefan; V, Maria C. B. Fragoso; PEREIRA, Maria A. A.; LI, Minghao; COSTA, Josefina Biarnes; JUHLIN, Carl Christofer; GROSS, David; VIOLANTE, Alice H. D.; KOCJAN, Tomaz; NGEOW, Joanne; YOEL, Uri; FRAENKEL, Merav; SIMSIR, Ilgin Yildirim; UGURLU, M. Umit; ZIAGAKI, Athanasia; DIAZ, Luis Robles; KUDLAI, Inna Stepanovna; GIMM, Oliver; SCHERBAUM, Christina Rebecca; ABEBE-CAMPINO, Gadi; BARBON, Giovanni; TASCHIN, Elisa; MALINOC, Angelica; KHUDIAKOVA, Natalia Valeryevna; V, Nikita Ivanov; PFEIFER, Marija; ZOVATO, Stefania; PLOECKINGER, Ursula; MAKAY, Ozer; GRINEVA, Elena; JARZAB, Barbara; JANUSZEWICZ, Andrzej; SHAH, Nalini; SEUFERT, Jochen; OPOCHER, Giuseppe; LARSSON, CatharinaIMPORTANCE Large studies investigating long-term outcomes of patients with bilateral pheochromocytomas treated with either total or cortical-sparing adrenalectomies are needed to inform clinical management. OBJECTIVE To determine the association of total vs cortical-sparing adrenalectomy with pheochromocytoma-specific mortality, the burden of primary adrenal insufficiency after bilateral adrenalectomy, and the risk of pheochromocytoma recurrence. DESIGN, SETTING, AND PARTICIPANTS This cohort study used data from a multicenter consortium-based registry for 625 patients treated for bilateral pheochromocytomas between 1950 and 2018. Data were analyzed from September 1, 2018, to June 1, 2019. EXPOSURES Total or cortical-sparing adrenalectomy. MAIN OUTCOMES AND MEASURES Primary adrenal insufficiency, recurrent pheochromocytoma, and mortality. RESULTS Of 625 patients (300 [48%] female) with a median (interquartile range [IQR]) age of 30 (22-40) years at diagnosis, 401 (64%) were diagnosed with synchronous bilateral pheochromocytomas and 224 (36%) were diagnosed with metachronous pheochromocytomas (median [IQR] interval to second adrenalectomy, 6 [1-13] years). In 505 of 526 tested patients (96%), germline mutationswere detected in the genes RET (282 patients [54%]), VHL (184 patients [35%]), and other genes (39 patients [7%]). Of 849 adrenalectomies performed in 625 patients, 324 (52%) were planned as cortical sparing and were successful in 248 of 324 patients (76.5%). Primary adrenal insufficiency occurred in all patients treated with total adrenalectomy but only in 23.5% of patients treated with attempted cortical-sparing adrenalectomy. A third of patients with adrenal insufficiency developed complications, such as adrenal crisis or iatrogenic Cushing syndrome. Of 377 patients who became steroid dependent, 67 (18%) developed at least 1 adrenal crisis and 50 (13%) developed iatrogenic Cushing syndrome during median (IQR) follow-up of 8 (3-25) years. Two patients developed recurrent pheochromocytoma in the adrenal bed despite total adrenalectomy. In contrast, 33 patients (13%) treated with successful cortical-sparing adrenalectomy developed another pheochromocytoma within the remnant adrenal after a median (IQR) of 8 (4-13) years, all of which were successfully treated with another surgery. Cortical-sparing surgery was not associated with survival. Overall survivalwas associated with comorbidities unrelated to pheochromocytoma: of 63 patients who died, only 3 (5%) died of metastatic pheochromocytoma. CONCLUSIONS AND RELEVANCE Patients undergoing cortical-sparing adrenalectomy did not demonstrate decreased survival, despite development of recurrent pheochromocytoma in 13%. Cortical-sparing adrenalectomy should be considered in all patients with hereditary pheochromocytoma.
- 5th International ACC Symposium: Future and Current Therapeutic Trials in Adrenocortical Carcinoma(2016) HOFF, Ana O.; BERRUTI, AlfredoAdrenocortical carcinoma (ACC) is a rare and complex disease associated with a high mortality rate. Despite intensive translational and clinical research, prognosis remains poor. Over the past decade, a significant effort has been made to develop multinational, collaborative studies to better understand the pathogenesis and clinical features of this rare disease in attempt to improve the therapeutic strategies and patient outcome. The results of both standard and newer treatments are discussed in this review as well as the recent discovery of pathways involved in ACC pathogenesis that provide the rationale to introduce new molecular target therapies. Finally, remaining issues regarding how to improve available therapies in adjuvant setting are raised and addressed.
- Phase 3 Trial of Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer(2023) HADOUX, J.; ELISEI, R.; BROSE, M. S.; HOFF, A. O.; ROBINSON, B. G.; GAO, M.; JARZAB, B.; ISAEV, P.; KOPECKOVA, K.; WADSLEY, J.; FUEHRER, D.; KEAM, B.; BARDET, S.; SHERMAN, E. J.; TAHARA, M.; HU, M. I.; SINGH, R.; LIN, Y.; SOLDATENKOVA, V; WRIGHT, J.; LIN, B.; MAEDA, P.; CAPDEVILA, J.; WIRTH, L. J.Background Selpercatinib, a highly selective, potent RET inhibitor, has shown efficacy in advanced RET-mutant medullary thyroid cancer in a phase 1-2 trial, but its efficacy as compared with approved multikinase inhibitors is unclear.Methods We conducted a phase 3, randomized trial comparing selpercatinib as first-line therapy with the physician's choice of cabozantinib or vandetanib (control group). Eligible patients had progressive disease documented within 14 months before enrollment. The primary end point in the protocol-specified interim efficacy analysis was progression-free survival, assessed by blinded independent central review. Crossover to selpercatinib was permitted among patients in the control group after disease progression. Treatment failure-free survival, assessed by blinded independent central review, was a secondary, alpha-controlled end point that was to be tested only if progression-free survival was significant. Among the other secondary end points were overall response and safety.Results A total of 291 patients underwent randomization. At a median follow-up of 12 months, median progression-free survival as assessed by blinded independent central review was not reached in the selpercatinib group and was 16.8 months (95% confidence interval [CI], 12.2 to 25.1) in the control group (hazard ratio for disease progression or death, 0.28; 95% CI, 0.16 to 0.48; P<0.001). Progression-free survival at 12 months was 86.8% (95% CI, 79.8 to 91.6) in the selpercatinib group and 65.7% (95% CI, 51.9 to 76.4) in the control group. Median treatment failure-free survival as assessed by blinded independent central review was not reached in the selpercatinib group and was 13.9 months in the control group (hazard ratio for disease progression, discontinuation due to treatment-related adverse events, or death, 0.25; 95% CI, 0.15 to 0.42; P<0.001). Treatment failure-free survival at 12 months was 86.2% (95% CI, 79.1 to 91.0) in the selpercatinib group and 62.1% (95% CI, 48.9 to 72.8) in the control group. The overall response was 69.4% (95% CI, 62.4 to 75.8) in the selpercatinib group and 38.8% (95% CI, 29.1 to 49.2) in the control group. Adverse events led to a dose reduction in 38.9% of the patients in the selpercatinib group, as compared with 77.3% in the control group, and to treatment discontinuation in 4.7% and 26.8%, respectively.Conclusions Selpercatinib treatment resulted in superior progression-free survival and treatment failure-free survival as compared with cabozantinib or vandetanib in patients with RET-mutant medullary thyroid cancer. (Funded by Loxo Oncology, a subsidiary of Eli Lilly; LIBRETTO-531 ClinicalTrials.gov number, NCT04211337.)
- Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study(2019) CASTINETTI, Frederic; WAGUESPACK, Steven G.; MACHENS, Andreas; UCHINO, Shinya; HASSE-LAZAR, Kornelia; SANSO, Gabriella; ELSE, Tobias; DVORAKOVA, Sarka; QI, Xiao Ping; ELISEI, Rossella; MAIA, Ana Luisa; GLOD, John; LOURENCO JR., Delmar Muniz; VALDES, Nuria; MATHIESEN, Jes; WOHLLK, Nelson; BANDGAR, Tushar R.; DRUI, Delphine; KORBONITS, Marta; DRUCE, Maralyn R.; BRAIN, Caroline; KURZAWINSKI, Tom; PATOCS, Atila; BUGALHO, Maria Joao; LACROIX, Andre; CARON, Philippe; FAINSTEIN-DAY, Patricia; CHAZOT, Francoise Borson; KLEIN, Marc; LINKS, Thera P.; LETIZIA, Claudio; FUGAZZOLA, Laura; CHABRE, Olivier; CANU, Letizia; COHEN, Regis; TABARIN, Antoine; UROIC, Anita Spehar; MAITER, Dominique; LABOUREAU, Sandrine; MIAN, Caterina; PECZKOWSKA, Mariola; SEBAG, Frederic; BRUE, Thierry; MIREBEAU-PRUNIER, Delphine; LECLERC, Laurence; BAUSCH, Birke; BERDELOU, Amandine; SUKURAI, Akihiro; VLCEK, Petr; KRAJEWSKA, Jolanta; BARONTINI, Marta; VARGAS, Carla Vaz Ferreira; VALERIO, Laura; CEOLIN, Lucieli; AKSHINTALA, Srivandana; HOFF, Ana; GODBALLE, Christian; JARZAB, Barbara; JIMENEZ, Camilo; ENG, Charis; IMAI, Tsuneo; SCHLUMBERGER, Martin; GRUBBS, Elizabeth; DRALLE, Henning; NEUMANN, Hartmut P.; BAUDIN, EricBackground Multiple endocrine neoplasia type 2B is a rare syndrome caused mainly by Met918Thr germline RET mutation, and characterised by medullary thyroid carcinoma, phaeochromocytoma, and extra-endocrine features. Data are scarce on the natural history of multiple endocrine neoplasia type 2B. We aimed to advance understanding of the phenotype and natural history of multiple endocrine neoplasia type 2B, to increase awareness and improve detection. Methods This study was a retrospective, multicentre, international study in patients carrying the Met918Thr RET variant with no age restrictions. The study was done with registry data from 48 centres globally. Data from patients followed-up from 1970 to 2016 were retrieved from May 1, 2016, to May 31, 2018. Our primary objectives were to determine overall survival, and medullary thyroid carcinoma-specific survival based on whether the patient had undergone early thyroidectomy before the age of 1 year. We also assessed remission of medullary thyroid carcinoma, incidence and treatment of phaeochromocytoma, and the penetrance of extra-endocrine features. Findings 345 patients were included, of whom 338 (98%) had a thyroidectomy. 71 patients (21%) of the total cohort died at a median age of 25 years (range <1-59). Thyroidectomy was done before the age of 1 year in 20 patients, which led to long-term remission (ie, undetectable calcitonin level) in 15 (83%) of 18 individuals (2 patients died of causes unrelated to medullary thyroid carcinoma). Medullary thyroid carcinoma-specific survival curves did not show any significant difference between patients who had thyroidectomy before or after 1 year (comparison of survival curves by log-rank test: p=0.2; hazard ratio 0.35; 95% CI 0.07-1.74). However, there was a significant difference in remission status between patients who underwent thyroidectomy before and after the age of 1 year (p<0.0001). There was a significant difference in remission status between patients who underwent thyroidectomy before and after the age of 1 year (p<0.0001). In the other 318 patients who underwent thyroidectomy after 1 year of age, biochemical and structural remission was obtained in 47 (15%) of 318 individuals. Bilateral phaeochromocytoma was diagnosed in 156 (50%) of 313 patients by 28 years of age. Adrenal-sparing surgery was done in 31 patients: three (10%) of 31 patients had long-term recurrence, while normal adrenal function was obtained in 16 (62%) patients. All patients with available data (n=287) had at least one extra-endocrine feature, including 106 (56%) of 190 patients showing marfanoid body habitus, mucosal neuromas, and gastrointestinal signs. Interpretation Thyroidectomy done at no later than 1 year of age is associated with a high probability of cure. The reality is that the majority of children with the syndrome will be diagnosed after this recommended age. Adrenal-sparing surgery is feasible in multiple endocrine neoplasia type 2B and affords a good chance for normal adrenal function. To improve the prognosis of such patients, it is imperative that every health-care provider be aware of the extra-endocrine signs and the natural history of this rare syndrome. The implications of this research include increasing awareness of the extra-endocrine symptoms and also recommendations for thyroidectomy before the age of 1 year.
- LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naive RET-mutant medullary thyroid cancer(2022) WIRTH, Lori J.; BROSE, Marcia S.; ELISEI, Rossella; CAPDEVILA, Jaume; HOFF, Ana O.; I, Mimi Hu; TAHARA, Makoto; ROBINSON, Bruce; GAO, Ming; XIA, Meng; MAEDA, Patricia; SHERMAN, EricSelpercatinib is a first-in-class, highly selective and potent, central nervous system-active RET kinase inhibitor. In the phase I/II trial, selpercatinib demonstrated clinically meaningful antitumor activity with manageable toxicity in heavily pre-treated and treatment-naive patients with RET-mutant medullary thyroid cancer (MTC). LIBRETTO-531 (NCT04211337) is a multicenter, open-label, randomized, controlled, phase III trial comparing selpercatinib to cabozantinib or vandetanib in patients with advanced/metastatic RET-mutant MTC. The primary objective is to compare progression-free survival (per RECIST 1.1) by blinded independent central review of patients with progressive, advanced, multikinase inhibitor-naive, RET-mutant MTC treated with selpercatinib versus cabozantinib or vandetanib. Key secondary objectives are to compare other efficacy outcomes (per RECIST 1.1) and tolerability of selpercatinib versus cabozantinib or vandetanib. Plain language summary: Selpercatinib (also known by the brand name Retevmo (R)/Retsevmo (R)) is a new treatment available in multiple countries for people with advanced or metastatic RET-mutant medullary thyroid cancer (MTC). Thyroid cancer starts in your thyroid gland and may spread or metastasize to other parts of the body, including lungs, bones, and occasionally the brain, which means the cancer is likely to be advanced. Advanced thyroid cancer can be driven by a gene in your body, one of which is RET. This is a summary of the LIBRETTO-531 study which compares selpercatinib, which is a strong and selective inhibitor of RET, with two approved drugs, cabozantinib and vandetanib. Patients with advanced or metastatic RET-mutant MTC who have not already received treatment with kinase inhibitors are being enrolled. This trial will evaluate how long people during and after treatment live with the disease without it getting worse. Selpercatinib may affect both healthy cells and tumor cells, which can result in side effects, which will also be evaluated in this study. This study is active and currently recruiting new patients.
- Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer(2015) SCHLUMBERGER, Martin; TAHARA, Makoto; WIRTH, Lori J.; ROBINSON, Bruce; BROSE, Marcia S.; ELISEI, Rossella; HABRA, Mouhammed Amir; NEWBOLD, Kate; SHAH, Manisha H.; HOFF, Ana O.; GIANOUKAKIS, Andrew G.; KIYOTA, Naomi; TAYLOR, Matthew H.; KIM, Sung-Bae; KRZYZANOWSKA, Monika K.; DUTCUS, Corina E.; HERAS, Begona de las; ZHU, Junming; SHERMAN, Steven I.Background Lenvatinib, an oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, fibroblast growth factor receptors 1 through 4, platelet-derived growth factor receptor a, RET, and KIT, showed clinical activity in a phase 2 study involving patients with differentiated thyroid cancer that was refractory to radioiodine (iodine-131). Methods In our phase 3, randomized, double-blind, multicenter study involving patients with progressive thyroid cancer that was refractory to iodine-131, we randomly assigned 261 patients to receive lenvatinib (at a daily dose of 24 mg per day in 28-day cycles) and 131 patients to receive placebo. At the time of disease progression, patients in the placebo group could receive open-label lenvatinib. The primary end point was progression-free survival. Secondary end points included the response rate, overall survival, and safety. Results The median progression-free survival was 18.3 months in the lenvatinib group and 3.6 months in the placebo group (hazard ratio for progression or death, 0.21; 99% confidence interval, 0.14 to 0.31; P<0.001). A progression-free survival benefit associated with lenvatinib was observed in all prespecified subgroups. The response rate was 64.8% in the lenvatinib group (4 complete responses and 165 partial responses) and 1.5% in the placebo group (P<0.001). The median overall survival was not reached in either group. Treatment-related adverse effects of any grade, which occurred in more than 40% of patients in the lenvatinib group, were hypertension (in 67.8% of the patients), diarrhea (in 59.4%), fatigue or asthenia (in 59.0%), decreased appetite (in 50.2%), decreased weight (in 46.4%), and nausea (in 41.0%). Discontinuations of the study drug because of adverse effects occurred in 37 patients who received lenvatinib (14.2%) and 3 patients who received placebo (2.3%). In the lenvatinib group, 6 of 20 deaths that occurred during the treatment period were considered to be drug-related. Conclusions Lenvatinib, as compared with placebo, was associated with significant improvements in progression-free survival and the response rate among patients with iodine-131-refractory thyroid cancer. Patients who received lenvatinib had more adverse effects. (Funded by Eisai; SELECT ClinicalTrials.gov number, NCT01321554.)
conferenceObject A phase 3, multicenter, double-blind, placebo-controlled trial of lenvatinib (E7080) in patients with I-refractory differentiated thyroid cancer (SELECT)(2014) SCHLUMBERGER, M.; TAHARA, M.; WIRTH, L.; ROBINSON, B.; BROSE, M.; ELISEI, R.; DUTCUS, C.; HERAS, B. de las; ZHU, J.; HABRA, M.; NEWBOLD, K.; SHAH, M. H.; HOFF, A. O.; GIANOUKAKIS, A. G.; KIYOTA, N.; TAYLOR, M.; KIM, S-B; KRZYZANOWSKA, M.; I, S. ShermanconferenceObject EFFICACY AND SAFETY OF LENVATINIB FOR THE TREATMENT OF PATIENTS WITH I-131-REFRACTORY DIFFERENTIATED THYROID CANCER WITH AND WITHOUT PRIOR VEGF-TARGETED THERAPY(2015) NEWBOLD, Kate; ELISEI, Rosella; TAYLOR, Matthew Hiram; KRZYZANOWSKA, Monika; SHAH, Manisha H.; HOFF, Ana O.; ROBINSON, Bruce; DUTCUS, Corina; SONG, James; HUGHES, Brett; HABRA, Mouhammed Amir- LIBRETTO-531: Selpercatinib in patients with treatment (Tx)-naive RET-mutant medullary thyroid cancer (MTC)(2020) HERNANDO, J.; TARASOVA, V.; HU, M. I.; SHERMAN, E. J.; BROSE, M. S.; ROBINSON, B.; TAHARA, M.; WIRTH, L. J.; SASHEGYI, A.; SOLDATENKOVA, V.; LIN, B. K.; WRIGHT, J.; HOFF, A. O.; LEBOULLEUX, S.; ELISEI, R.; CAPDEVILA, J.
- Randomized phase III study of selpercatinib versus cabozantinib or vandetanib in advanced, kinase inhibitornaive, RET-mutant medullary thyroid cancer(2023) HADOUX, J.; ELISEI, R.; BROSE, M. S.; HOFF, A.; ROBINSON, B.; GAO, M.; JARZAB, B.; ISAEV, P.; KOPECKOVA, K.; WADSLEY, J.; FUHRER, D.; KEAM, B.; SHERMAN, E. J.; TAHARA, M.; HU, M. I.; LIN, Y.; MAEDA, P.; WIRTH, L. J.; CASTILLON, J. Capdevila